Public information presented according to the provisions of Directive 2001/18/EC
Trial reference:
A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC)
Doc type: